Pernix Sleep, Inc. Uncategorized Contracts & Agreements
38 Contracts & Agreements
- [To be separately provided to the Investor] (Filed With SEC on July 20, 2012)
- Sincerely, /s/ Richard W. Pascoe Richard W. Pascoe President and Chief Executive Officer (Filed With SEC on November 25, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on November 4, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on November 4, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on November 4, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on November 4, 2011)
- Supplement One (Filed With SEC on February 11, 2011)
- Current assets (Filed With SEC on November 10, 2010)
- Current assets (Filed With SEC on November 10, 2010)
- CO-PROMOTION AGREEMENT (Filed With SEC on August 25, 2010)
- Supplement One (Filed With SEC on July 21, 2010)
- 6,000,000 Shares (Filed With SEC on March 31, 2010)
- Maximize the value of Silenor. Silenor was approved by the FDA for the treatment of insomnia characterized by difficulty with sleep maintenance in March 2010. We believe that... (Filed With SEC on March 19, 2010)
- Current assets (Filed With SEC on August 7, 2009)
- Current assets (Filed With SEC on August 7, 2009)
- Current assets (Filed With SEC on August 7, 2009)
- Number of Options (Filed With SEC on July 21, 2009)
- Current assets (Filed With SEC on May 8, 2009)
- Current assets (Filed With SEC on May 8, 2009)
- Exhibit Number (Filed With SEC on April 24, 2009)
- Exhibit Number (Filed With SEC on April 24, 2009)
- Maximize the value of Silenor. We have successfully completed our four Phase 3 clinical trials for Silenor in the treatment of insomnia. We designed our Phase 3 clinical program... (Filed With SEC on March 13, 2009)
- Maximize the value of Silenor. We have successfully completed our four Phase 3 clinical trials for Silenor in the treatment of insomnia. We designed our Phase 3 clinical program... (Filed With SEC on March 13, 2009)
- Maximize the value of Silenor. We have successfully completed our four Phase 3 clinical trials for Silenor in the treatment of insomnia. We designed our Phase 3 clinical program... (Filed With SEC on March 13, 2009)
- Maximize the value of Silenor. We have successfully completed our four Phase 3 clinical trials for Silenor in the treatment of insomnia. We designed our Phase 3 clinical program... (Filed With SEC on March 13, 2009)
- Results of Operations and Financial Condition (Filed With SEC on August 7, 2008)
- Results of Operations and Financial Condition (Filed With SEC on August 7, 2008)
- in a clinical trial to evaluate SILENORtm in the treatment of adults (229) with chronic insomnia in a sleep laboratory setting, SILENORtm demonstrated a statistically significant... (Filed With SEC on March 12, 2008)
- in a clinical trial to evaluate SILENORtm in the treatment of adults (229) with chronic insomnia in a sleep laboratory setting, SILENORtm demonstrated a statistically significant... (Filed With SEC on March 12, 2008)
- in a clinical trial to evaluate SILENORtm in the treatment of adults (229) with chronic insomnia in a sleep laboratory setting, SILENORtm demonstrated a statistically significant... (Filed With SEC on March 12, 2008)
- in a clinical trial to evaluate SILENORtm in the treatment of adults (229) with chronic insomnia in a sleep laboratory setting, SILENORtm demonstrated a statistically significant... (Filed With SEC on March 12, 2008)
- in a clinical trial to evaluate SILENORtm in the treatment of adults (229) with chronic insomnia in a sleep laboratory setting, SILENORtm demonstrated a statistically significant... (Filed With SEC on March 12, 2008)
- SOMAXON PHARMACEUTICALS, INC. (Filed With SEC on April 3, 2007)
- SOMAXON PHARMACEUTICALS, INC. (Filed With SEC on January 29, 2007)
- W I T N E S S E T H: (Filed With SEC on November 14, 2006)
- Exhibit No (Filed With SEC on June 28, 2006)
- SOMAXON PHARMACEUTICALS, INC. (Filed With SEC on May 16, 2006)
- Current assets (Filed With SEC on May 11, 2006)